Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
A target concentration of 40 ng/ml 25(OH)D may prevent development of AIrA. We also demonstrate that AIrA is genetically determined: single nucleotide polymorphisms located in genes encoding key factors for the metabolism of estrogens and … Leer más